Powerful... Meet simple
In the human heart, a coordinated contraction is required for efficient circulation. Slowed or disrupted conduction can lead to irregular heart beats, known as arrhythmia, making conduction a key component of cardiac assessment in vitro. Providing up to 64 recording sites in each well,Maestro MEA is ideal for examining cardiomyocyte beat propagation across a syncytium. Measure changes in propagation patterns and conduction velocity in response to pharmacological interrogation, and during cardiomyocyte differentiation and maturation.
In a cardiomyocyte-MEA assay, the cardiac field potential signal arises from the propagation of the cardiac action potential across the functional syncytium, much in the same way the clinical ECG arises from the propagation of the cardiac action potential across the heart. The field potential signal has clear markers for depolarization and repolarization which enable the quantification of important beating parameters in vitro. In the multi-site, blinded CiPA Myocyte studies, the Maestro MEA field potential assay played a pivotal role in demonstrating the utility of human stem cell-derived cardiomyocytes to detect drug-induced arrhythmia effects.
Axion's patent-pending Local Extracellular Action Potential (LEAP) assay allows you to record extracellular action potential waveforms, which are stable for 10 to 20 minutes or more. The new LEAP assay signal allows quantification of action potential morphology and characterization of complex repolarization irregularities such as early afterdepolarizations (EADs). LEAP is label-free and doesn't disrupt the underlying biology, meaning you can focus on the pharmacology and not on dye-drug or dye-biology interactions.
Cardiomyocytes cultured on MEAs create an accessible platform for studying heart beats in a dish. Cardiomyocyte assays rely on evaluation of parameters, such as repolarization timing, that are tightly coupled to beat rate. Controlling beat rate allows you to increase physiological relevance and reduce well-to-well variability. Furthermore, the ability to systemically vary beat rate enables detection of use dependent (i.e. beat rate dependent) drug effects.
The Lumos optical stimulation system delivers precisely controlled light to each well of a 24-, or 48-well microplate. The Maestro MEA platform provides non-invasive electrical activity recordings across each cultured cardiomyocyte network. Together, these devices seamlessly pair to unlock entirely new assay capabilities, all in a high-throughput format. Combine the Lumos and Maestro to precisely control cardiomyocyte beat rate while simultaneously recording electrical responses.
Built on Axion’s latest chip technology, BioCore v4, the next generation Maestro MEA systems makes it even easier to perform measurements from excitable cells in your own lab.
With “one button setup,” the cell environment automatically adjusts on plate docking, and plate usage is automatically logged for convenient experiment tracking. Both Maestro Pro and Edge run Axion’s most advanced data acquisition and analysis software, AxIS Navigator.